Neuromyelitis optica spectrum disorder (NMOSD) is not a hereditary disease in the traditional sense. It does not follow a predictable inheritance pattern where a parent passes it directly to a child. The vast majority of cases appear sporadically, meaning they develop in people with no family history of the condition. However, genetics do play a supporting role: roughly 3% of NMOSD cases are familial, occurring in more than one member of the same family, which is higher than you’d expect based on how rare the condition is in the general population.
Why NMO Is Not a Classic Inherited Disease
Inherited diseases like sickle cell anemia or cystic fibrosis follow clear patterns. If you carry certain gene variants, you will develop the disease or pass it on in a predictable way. NMOSD doesn’t work like this. There is no single gene responsible for causing it, and having a relative with the condition does not mean you will develop it.
What researchers describe instead is a “complex genetic etiology.” This means multiple genes, each contributing a small amount of risk, may interact with environmental and immune system factors to trigger the disease. The result is that NMOSD can occasionally cluster in families, but it does so unpredictably and infrequently. A multinational study of 386 patients found that 3% had a familial form. A single-center study from Thailand identified 6 familial cases among 165 patients, a rate of 3.6%. Another center reported a lower rate of 0.8%. These numbers confirm that family clustering exists but remains uncommon.
Genetic Variants That Raise Susceptibility
Although no gene causes NMOSD outright, certain immune system genes appear to make people more susceptible. The strongest associations involve HLA genes, which help your immune system distinguish your own cells from foreign invaders. Variations in these genes can influence whether the immune system misfires, which is central to how NMOSD develops.
One case-control study found that carrying the HLA-DQB1*04 allele tripled the odds of developing NMOSD compared to people without it. Interestingly, a related variant called HLA-DQB1*03 appeared to have a protective effect, meaning people who carry it may be less likely to develop the condition. These findings suggest that your specific combination of immune system genes nudges your risk up or down, rather than determining your fate.
Genetic Risk Varies by Ethnicity
Different populations carry different HLA variants, and the specific gene variants linked to NMOSD susceptibility are not the same across ethnic groups. In Japanese and Chinese patients, susceptibility is associated with the HLA-DPB1*0501 allele. In Caucasian, Afro-Caribbean, and Indian patients, the associated variant is HLA-DPB1*03 instead. The Japanese-linked variant shows no association with NMOSD in Caucasian populations at all.
This explains part of why NMOSD affects different populations at different rates and with different clinical features. The underlying genetic architecture of risk appears to be population-specific, which complicates efforts to identify universal genetic risk factors. It also means that findings from one ethnic group can’t simply be applied to another.
Family History of Autoimmune Disease Matters More
NMOSD is an autoimmune condition. Your immune system produces antibodies (most commonly against a protein called aquaporin-4) that attack your own nerve tissue, particularly in the optic nerves and spinal cord. While the disease itself rarely runs in families, a tendency toward autoimmune disease in general does have a genetic component.
If your family has a history of autoimmune conditions like lupus, thyroid disease, or myasthenia gravis, that broader autoimmune predisposition may be more relevant than looking for NMOSD specifically. The genetic risk you inherit is less about NMO in particular and more about an immune system that is primed to attack the body’s own tissues. Which autoimmune disease develops, if any, depends on a combination of additional genetic factors and environmental triggers that researchers are still working to identify.
No Genetic Test Can Predict NMO
There is currently no genetic test that can tell you whether you will develop NMOSD. The international diagnostic criteria for the condition rely on clinical symptoms (such as optic neuritis or inflammation of the spinal cord), MRI findings, and blood tests for aquaporin-4 antibodies. Genetic testing plays no role in diagnosis or screening.
This means that if you have a family member with NMOSD, there is no recommended genetic screening for yourself or your children. The familial risk, while real, is too small and too genetically complex for current testing to be useful. The most practical step is simply being aware of the symptoms: sudden vision loss in one or both eyes, episodes of weakness or numbness in the limbs, and prolonged nausea or hiccups (which can signal spinal cord inflammation). Early recognition leads to earlier treatment, which significantly affects long-term outcomes.
What the 3% Familial Rate Means for You
If you or someone in your family has been diagnosed with NMOSD, the 3% familial rate means that the overwhelming majority of relatives will never develop the condition. To put it in perspective, NMOSD affects roughly 1 in 100,000 people in the general population. The familial clustering rate is higher than that baseline, which tells researchers that genetics contribute something, but the absolute risk to any individual family member remains very low.
The bottom line: NMOSD has a genetic component, but it is not hereditary in the way most people mean when they ask that question. You cannot “pass it on” to your children through a single gene. What you may pass on is a subtle immune system profile that, combined with the right (or wrong) environmental circumstances, could slightly increase susceptibility. For the vast majority of families affected by NMOSD, the condition will not appear in another family member.